Site Editor

Rebecca Olin, MD, MS

Advertisement
Advertisement

Musa Yilmaz, MD, on Quizartinib Plus Decitabine With or Without Venetoclax for FLT3-ITD–Mutated AML

Posted: Thursday, December 10, 2020

Musa Yilmaz, MD, of The University of Texas MD Anderson Cancer Center, discusses his study findings on the activity of quizartinib, decitabine, and venetoclax in patients with FLT3-ITD–mutated acute myeloid leukemia. He describes how these early results compare with other regimens used in this setting, toxicities, and whether patients need referral to a specialized center for this therapy.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.